Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Panacea Biotec Pharma Limited
WARNING LETTER
•Panacea Biotec Pharma Limited•February 20, 2020

Panacea Biotec Pharma Limited – FDA Warning Letter, Feb 20, 2020

Record Details

The FDA issued a Warning Letter to Panacea Biotec Limited following an inspection from February 10-20, 2020, at their facility in Tehsil Nalagarh, India. The letter identifies significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals, rendering their drug products adulterated under 21 U.S.C. 351(a)(2)(B).

Key violations include: 1. **Inadequate Laboratory Controls (21 CFR 211.160(b))**: The firm failed to establish scientifically sound laboratory controls. Specifically, they lacked data on microorganism identification from aseptic processing, identifying only 1 out of 6360 isolates in 2019 from the ISO 7 area. They also used an incomplete photographic library for visual identification and failed to record basic microbial differentiation data like gram stain or spore-forming characteristics. Additionally, analysts failed to perform critical steps (vortexing, using calibrated timers) during endotoxin analysis, and the gel clot method lacked sufficient instructions. The firm's response was deemed inadequate for not committing to identifying all isolates to at least the genus level and for not providing a retrospective review of laboratory practices and analyst competencies.

2. **Inadequate Environmental Monitoring (21 CFR 211.42(c)(10)(iv))**: The firm lacked an adequate system for monitoring environmental conditions in aseptic processing areas.

Company
Panacea Biotec Pharma Limited
Inspection date
February 20, 2020
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 9bfb3b4c-f0cf-4c64-b180-b75c3048009e

Violation Codes8
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.160(b)21 CFR 211.42(c)(10)(iv)FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Other documents for Panacea Biotec Pharma Limited
  • 483 - 2023-10-12October 12, 2023
  • 483 - 2022-06-08June 8, 2022
  • 483 - 2020-02-20February 20, 2020
  • 483 - 2019-08-09August 9, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Panacea Biotec Pharma Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.